Slide 1: FY’13 Results
FY’13 Results The Diagnostic Specialist ; {Ol
Slide 2: Disclaimer
DISCLAIMER These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Overview
OVERVIEW Highlights 2013 Main Topics Revenues Revenues: breakdown by technology Revenues: breakdown by geography Installed base expansion Profitability profile Business Development Products Development FY 2013 Financials FY 2014 Company Guidance 3
Slide 4: 2013 Main Topics
2013 Main Topics Revenues: growing as expected (+2.5% at CER) Liaison & Liaison XL placements FY’13 guidance achieved: Ongoing worldwide success of Liaison XL and confirmation growth between +2% and +4% at CER of interest on Liaison Placements FY’13 Total at Dec 31, 2013 CLIA ex Vit D: (+17.6% at CE
Slide 5: Revenues
Revenues Q4’13 FY’13 vs. vs. Q4’12 FY’12 CLIA ex Vitamin D sales up at sustained pace on FY’13, with an acceleration on Q4’13 @ current +2.1% +0.3% Vitamin D trend negative as expected (pricing erosion), but decelerating when comparing FY’13 vs. FY’12 SALES Instruments and consumables sales up; posi
Slide 6: Revenues: Breakdown by Technology
Revenues: Breakdown by Technology Q4’13 FY’13 vs. vs. Q4’12 FY’12 • Strong growth in FY’13 in all geographies, with positive trend @ current +20.0% +16.1% of all products throughout the different clinical areas CLIA ex Vit D • Success leveraging on menu completeness and Liaison XL @ CER +22.2% +17.6
Slide 7: Revenues: Breakdown by Geography (1 of 2)
Revenues: Breakdown by Geography (1 of 2) Q4’13 vs. FY’13 vs. Q4’13 vs. FY’13 vs. Q4’12 FY’12 Q4’12 FY’12 • Strong and steady growth in 2013 Europe +5.4% +4.5% Germany +21.3% +13.7% • Strong growth of Infectious Diseases and Endocrinology products • Strong growth of Vitamin D • Substantial growth of
Slide 8: Revenues: Breakdown by Geography (2 of 2)
Revenues: Breakdown by Geography (2 of 2) Q4’13 vs. FY’13 vs. Q4’13 vs. FY’13 vs. Q4’12 FY’12 Q4’12 FY’12 Apac +24.9% +17.3% China +33.1% +20.1% • Growth of CLIA products doubled in 2013, more than offsetting the slowdown of Murex • Success of LIASON XL installments (+25 units installed in 2013) Aus
Slide 9: Installed Base Expansion
INSTALLED BASE expansion Total units at Net placements in Net placements in Total units at December 31, 2012 Q4’13 FY’13 December 31, 2013 4,135 +1 +62 4,197 605 +65 +470 1,075 TOTAL 4,740 +66 +532 5,272 9
Slide 10: Profitability Profile
PROFITABILITY PROFILE Q4’12 Q4’13 FY’12 FY’13 Statutory 35.8% 36.6% +80bps 39.1% 37.5% -160bps EBITDA margin Excluding Molecular Business, at 37.2% 38.8% +160bps 40.7% 39.7% -100bps CER (*) Solid and strong Group marginality driven by: Reagents confirming steady and high margin levels in FY’13 Despi
Slide 11: Overview
OVERVIEW Highlights 2013 Main Topics Revenues Revenues: breakdown by technology Revenues: breakdown by geography Installed base expansion Profitability profile Business Development Products Development FY 2013 Financials FY 2014 Company Guidance 11
Slide 12: FY’13 Business Development (1 of 2)
FY’13 Business Development (1 of 2) 5-year agreement with Roche Connectivity of Liaison XL® System to cobas 8100® automated workflow series in High Volume Laboratories requesting fully automation of diagnostic processes, analytical set-up flexibility and broader menu of routine and specialty assays
Slide 13: FY’13 Business Development (2 of 2)
FY’13 Business Development (2 of 2) 3-year extension of agreement with LabCorp Expansion of Liaison XL menu offering to LabCorp, while maintaining existing Vitamin D business 15 new assays in addition to the current menu for LabCorp, expanding the offering in new clinical areas US Market playing a c
Slide 14: Overview
OVERVIEW Highlights 2013 Main Topics Revenues Revenues: breakdown by technology Revenues: breakdown by geography Installed base expansion Profitability profile Business Development Products Development FY 2013 Financials FY 2014 Company Guidance
Slide 15: FY’13 Products Development
FY’13 Products Development Expansion of Immunodiagnostics menu with key and unique specialty products + Menu expansion in key markets (USA, China, Brazil) Chagas Specialty test for a widespread infection in Latin America Enrichment of infectious diseases menu on Liaison analyzers Chlamydia Trachomat
Slide 16: Overview
OVERVIEW Highlights 2013 Main Topics Revenues Revenues: breakdown by technology Revenues: breakdown by geography Installed base expansion Profitability profile Business Development Products Development FY 2013 Financials FY 2014 Company Guidance 16
Slide 17: FY’13 Results: Income Statement
FY’13 Results: Income Statement €/mln FY Change 2013 2012 amount % Net revenues 434.8 433.8 +1.1 +0.3% Gross profit 299.7 297.3 +2.3 +0.8% Gross margin 68.9% 68.5% +0.4% S&M (85.6) (82.1) -3.5 +4.3% R&D (23.9) (23.4) -0.6 +2.4% G&A (49.7) (48.2) -1.5 +3.1% Total operating expenses (159.2) (153.7) -5
Slide 18: FY’13 Results: Balance Sheet
FY’13 Results: Balance Sheet €/mln 12/31/2013 12/31/2012 Total intangible assets 119.4 125.3 Total tangible assets 66.3 65.3 Other non-current assets 23.2 22.4 Net Working Capital 141.7 137.6 Other non-current liabilities (34.4) (32.6) Net Capital Employed 316.2 318.0 Net Financial Position 98.0 47.
Slide 19: FY’13 Results: Cash Flow Statement
FY’13 Results: Cash Flow Statement €/mln FY Change in value 2013 2012 Cash and cash equivalents at beginning of period 104.6 64.1 +40.5 Operating activities 107.7 110.6 -2.9 Investing activities (29.9) (30.3) +0.3 Financing activities (77.3) (32.3) -45.0 Acquisitions of companies and business operat
Slide 20: Overview
OVERVIEW Highlights 2013 Main Topics Revenues Revenues: breakdown by technology Revenues: breakdown by geography Installed base expansion Profitability profile Business Development Products Development FY 2013 Financials FY 2014 Company Guidance 20
Slide 21: FY 2014 Guidance
FY 2014 GUIDANCE Revenues: Growth between 3% and 5% at CER compared with 2013 EBITDA: Growth equal to. ca. 3% at CER compared with 2013 Liaison / Liaison XL installed base: ca. 500 21